

CITATION REPORT

List of articles citing

Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)

DOI: 10.1161/circulationaha.113.004406
Circulation, 2014, 129, 635-42.

Source: <https://exaly.com/paper-pdf/59136629/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
294	Response to letter regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)". <i>Circulation</i> , 2014 , 130, e152	16.7	2
293	Update on the NCEP ATP-III emerging cardiometabolic risk factors. 2014 , 12, 115		32
292	Letter by Giral et al regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)". <i>Circulation</i> , 2014 , 130, e151	16.7	1
291	Lipoprotein(a): there's life in the old dog yet. <i>Circulation</i> , 2014 , 129, 619-21	16.7	16
290	Lipoprotein(a): an important cardiovascular risk factor and a clinical conundrum. 2014 , 43, 949-62		24
289	Latest developments in the treatment of lipoprotein (a). <i>Current Opinion in Lipidology</i> , 2014 , 25, 452-60	4.4	28
288	Lipoprotein (a): gene genie. <i>Current Opinion in Lipidology</i> , 2014 , 25, 289-96	4.4	13
287	Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). 2014 , 114, 711-5		154
286	LDL cholesterol: controversies and future therapeutic directions. 2014 , 384, 607-617		181
285	Lipoprotein(a) as a therapeutic target in cardiovascular disease. 2014 , 18, 747-57		14
284	Lipoprotein(a) in various conditions: to keep a sense of proportions. <i>Atherosclerosis</i> , 2014 , 234, 249-51	3.1	17
283	2015 Meet-The-Professor: Endocrine Case Management. 2015 ,		
282	Dissecting lipid and lipoprotein issues in women: an in utero-through-menopause journey. 2015 , 10, 431-448		
281	Statins in Type 2 Diabetes. 2015 ,		
280	Lipoproteins and Cardiovascular Disease Risk. 2015 , 57-65		
279	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. <i>Journal of Clinical Lipidology</i> , 2015 , 9, S1-122.e1	4.9	293
278	Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2638-2651	15.1	123

277	Development and rescue of human familial hypercholesterolaemia in a xenograft mouse model. 2015 , 6, 7339		38
276	Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. 2015 , 386, 1472-83		304
275	Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis. 2015 , 35, 996-1001		86
274	Lipoprotein(a)-clinical aspects and future challenges. 2015 , 10, 26-32		12
273	Elevated oxidative stress among coronary artery disease patients on statin therapy: A cross sectional study. 2015 , 67, 227-32		10
272	Lipoprotein(a)--An independent causal risk factor for cardiovascular disease and current therapeutic options. 2015 , 18, 263-7		40
271	Lipids, blood pressure and kidney update 2014. 2015 , 95-96, 111-25		70
270	A Not-So-Little Role for Lipoprotein(a) in the Development of Calcific Aortic Valve Disease. <i>Circulation</i> , 2015 , 132, 621-3	16.7	15
269	Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia. 2015 , 278, 166-73		69
268	3. Diagnostische Verfahren. 2016 ,		
267	Recurrent Embolic Strokes of Undetermined Source in a Patient with Extreme Lipoprotein(a) Levels. 2016 , 7, 144		1
266	Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk. 2016 , 23, 157-64		38
265	Structure, function, and genetics of lipoprotein (a). <i>Journal of Lipid Research</i> , 2016 , 57, 1339-59	6.3	204
264	Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options. 2016 , 70, 967-977		20
263	PCSK9 inhibitors in the prevention of cardiovascular disease. 2016 , 42, 405-19		19
262	Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. 2016 , 18, C2-C12		56
261	Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 1011-1021	4.9	82
260	Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism. 2016 , 12, 467-84		22

259	Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease. 2016 , 30, 101-8		21
258	PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia. <i>Atherosclerosis</i> , 2016 , 254, 249-253	3.1	42
257	No small task: therapeutic targeting of Lp(a) for cardiovascular disease. 2016 , 388, 2211-2212		10
256	Increased risk of coronary artery calcification progression in subjects with high baseline Lp(a) levels: The Kangbuk Samsung Health Study. 2016 , 222, 233-237		11
255	The re-emergence of lipoprotein(a) in a broader clinical arena. <i>Progress in Cardiovascular Diseases</i> , 2016 , 59, 135-144	8.5	19
254	Cardiovascular Disease, Mortality Risk, and Healthcare Costs by Lipoprotein(a) Levels According to Low-density Lipoprotein Cholesterol Levels in Older High-risk Adults. 2016 , 39, 413-20		15
253	Lipoprotein(a) and Increased Cardiovascular Risk in Women. 2016 , 39, 96-102		9
252	Familial combined hyperlipidemia and hyperlipoprotein(a) as phenotypic mimics of familial hypercholesterolemia: Frequencies, associations and predictions. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 1329-1337.e3	4.9	32
251	Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease. 2016 , 15, 165		14
250	Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations. 2016 , 80, 512-8		51
249	Lipoprotein(a): Revisiting a Next Therapeutic Target. 2016 , 80, 329-31		2
248	Pharmacogenomics of Rosuvastatin: A Glocal (Global+Local) African Perspective and Expert Review on a Statin Drug. 2016 , 20, 498-509		9
247	Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. 2016 , 388, 2239-2253		426
246	Serum levels of Lp(a) are related to waist circumference in NAFLD patients with low prevalence of co-morbidities. 2016 , 76, 544-552		2
245	Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol. <i>Atherosclerosis</i> , 2016 , 251, 119-123	3.1	14
244	Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease. 2016 , 18, 69		9
243	Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. 2016 , 7, 11122		335
242	PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo: An Effect Blunted by Alirocumab. <i>JACC Basic To Translational Science</i> , 2016 , 1, 419-427	8.7	70

241	Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United States. 2016 , 36, 2239-2245		75
240	The relationship between Lp(a) and CVD outcomes: a systematic review. 2016 , 15, 95		38
239	Lipoprotein (a), an independent cardiovascular risk marker. 2016 , 2, 7		18
238	PCSK9 and Lipoprotein(a): The Plot Thickens. 2016 , 119, 3-6		4
237	Effects of Rosuvastatin Versus Atorvastatin, Alone or in Combination, on Lipoprotein (a). 2016 , 50, 609-15		4
236	Accelerated atherosclerosis and elevated lipoprotein (a) after liver transplantation. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 434-7	4.9	2
235	Current therapies for lowering lipoprotein (a). <i>Journal of Lipid Research</i> , 2016 , 57, 1612-8	6.3	54
234	From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk. 2016 , 118, 732-49		135
233	Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D Study. 2016 , 31, 1901-1908		22
232	Lipids, Lipoproteins, and Cardiovascular Disease: Clinical Pharmacology Now and in the Future. 2016 , 101, 804-14		28
231	Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases. 2016 , 30, 87-100		105
230	Lipoprotein(a) levels predict adverse vascular events after acute myocardial infarction. 2016 , 31, 1923-1929		20
229	Lipoprotein(a) and Heart Failure: Another Reason to Study Interventions in Patients With Very High Levels of Lipoprotein(a)?. 2016 , 4, 88-9		
228	Meta-Analysis Comparing Rosuvastatin and Atorvastatin in Reducing Concentration of C-Reactive Protein in Patients With Hyperlipidemia. 2016 , 67, 526-35		8
227	Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 147-158	15.1	27
226	The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies. 2017 , 131, 261-268		29
225	Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. 2017 , 15, 22		49
224	Plasma lipoprotein(a) levels in patients with homozygous autosomal dominant hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 507-514	4.9	12

223	A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 692-711	15.1	396
222	Hyperlipoproteinaemia(a) - apheresis and emerging therapies. 2017 , 12, 12-17		5
221	Genetics of Dyslipidemia and Ischemic Heart Disease. 2017 , 19, 46		13
220	OxLDL-derived lysophosphatidic acid promotes the progression of aortic valve stenosis through a LPAR1-RhoA-NF- κ B pathway. 2017 , 113, 1351-1363		48
219	Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). <i>Circulation</i> , 2017 , 135, 2494-2504	16.7	126
218	Advanced lipoprotein testing for cardiovascular diseases risk assessment: a review of the novel approaches in lipoprotein profiling. 2017 , 55, 1453-1464		13
217	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. 2017 , 5, 534-543		69
216	Lipoprotein(a) and cardiovascular mortality: mystery still unsolved. 2017 , 5, 489-490		1
215	Lipoprotein(a): the revenant. <i>European Heart Journal</i> , 2017 , 38, 1553-1560	9.5	89
214	Ethnicity, lipids and cardiovascular disease. <i>Current Opinion in Lipidology</i> , 2017 , 28, 225-230	4.4	17
213	Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease. <i>Atherosclerosis</i> , 2017 , 260, 67-74	3.1	50
212	Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 667-673	4.9	32
211	Recycling of Apolipoprotein(a) After PlgRKT-Mediated Endocytosis of Lipoprotein(a). 2017 , 120, 1091-1102		55
210	Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. 2017 , 22, 1-26		31
209	Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a). <i>European Heart Journal</i> , 2017 , 38, 3555-3559	9.5	15
208	Partitioning the Genetic Architecture of Plasma Lipoprotein(a) and Kringle IV Type 2 Repeats: Implications for Therapeutic Lowering. 2017 , 63, 1792-1794		
207	The renaissance of lipoprotein(a): Brave new world for preventive cardiology?. 2017 , 68, 57-82		46
206	Usefulness of Lipoprotein(a) for Predicting Clinical Outcomes After Endovascular Therapy for Aortoiliac Atherosclerotic Lesions. 2017 , 24, 793-799		8

205	CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects. 2017 , 37, 1770-1775		43
204	Practical recommendations for the management of cardiovascular risk associated with atherogenic dyslipidemia, with special attention to residual risk. Spanish adaptation of a European Consensus of Experts. 2017 , 29, 168-177		5
203	Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	70
202	Lipoprotein(a)-apheresis in the light of new drug developments. 2017 , 30, 38-43		12
201	Practical recommendations for the management of cardiovascular risk associated with atherogenic dyslipidemia, with special attention to residual risk. Spanish adaptation of a European Consensus of Experts. 2017 , 29, 168-177		1
200	Pathobiology of Lp(a) in calcific aortic valve disease. 2017 , 15, 797-807		17
199	Antisense Oligonucleotides for the Treatment of Hypertriglyceridemia and Hyperlipoproteinemia(a). 2017 , 3, 458-468		2
198	Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN. <i>Atherosclerosis</i> , 2017 , 263, 137-144	3.1	29
197	Lipoprotein(a) Levels and Recurrent Vascular Events After First Ischemic Stroke. 2017 , 48, 36-42		12
196	Lp(a) in Childhood. <i>Current Cardiovascular Risk Reports</i> , 2017 , 11, 1	0.9	0
195	Relationship between Syntax Score and prognostic localization of coronary artery lesions with conventional risk factors, plasma profile markers, and carotid atherosclerosis (CAPP Study 2). 2018 , 257, 306-311		6
194	Lipoprotein(a) level associates with coronary artery disease rather than carotid lesions in patients with familial hypercholesterolemia. 2018 , 32, e22442		9
193	Is Lipoprotein(a) Ready for Prime-Time Use in the Clinic?. 2018 , 36, 287-298		10
192	Lipoprotein(a) in clinical practice: New perspectives from basic and translational science. 2018 , 55, 33-54		15
191	Interleukin-1 genotypes modulate the long-term effect of lipoprotein(a) on cardiovascular events: The Ioannina Study. <i>Journal of Clinical Lipidology</i> , 2018 , 12, 338-347	4.9	11
190	NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 177-192	15.1	203
189	Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting. 2018 , 78, 215-229		22
188	LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins. <i>Circulation</i> , 2018 , 138, 1839-1849	16.7	40

187	Lipoprotein(a): A missing culprit in the management of athero-thrombosis?. 2018 , 233, 2966-2981		39
186	Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. <i>Journal of Clinical Lipidology</i> , 2018 , 12, 130-136	4.9	27
185	Lipoprotein (a) and Low-density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease. 2019 , 49, e13053		6
184	Lipoproteins in Cardiovascular Calcification: Potential Targets and Challenges. 2018 , 5, 172		18
183	Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. 2018 , 392, 1311-1320		208
182	Lipoprotein(a) Is Risky, but What Do We Do About It?. <i>Current Cardiovascular Risk Reports</i> , 2018 , 12, 1	0.9	1
181	Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal. <i>Journal of Clinical Lipidology</i> , 2018 , 12, 1358-1366	4.9	20
180	Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. 2018 , 64, 1006-1033		124
179	Elevated plasma lipoprotein(a) levels were associated with increased risk of cardiovascular events in Chinese patients with stable coronary artery disease. <i>Scientific Reports</i> , 2018 , 8, 7726	4.9	21
178	Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. <i>European Heart Journal</i> , 2018 , 39, 2589-2596	8.5	56
177	Lipoprotein(a) and Cardiovascular Risk Prediction Among Women. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 287-296	15.1	48
176	Refining Lipoprotein(a) Associated Cardiovascular Risk in Women. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 297-299	15.1	2
175	PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate. 2018 , 132, 1075-1083		30
174	Which Lipids Should Be Analyzed for Diagnostic Workup and Follow-up of Patients with Hyperlipidemias?. 2018 , 20, 88		10
173	Lp(a): Addressing a Target for Cardiovascular Disease Prevention. 2019 , 21, 102		10
172	Advanced Lipid Thinking Prior to Incorporating Advanced Lipid Testing. 2019 , 132, 1279-1284		
171	Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction. 2019 , 71, 99-112		16
170	Statin treatment increases lipoprotein(a) levels in subjects with low molecular weight apolipoprotein(a) phenotype. <i>Atherosclerosis</i> , 2019 , 289, 201-205	3.1	24

169	Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk. 2019 , 21, 38		
168	Baseline and on-statin treatment lipoprotein(a) levels for predicting cardiovascular events in patients with familial hypercholesterolemia. <i>Atherosclerosis</i> , 2019 , 291, 27-33	3.1	8
167	Catering to Your Concerns. 2019 , 3, 1-21		1
166	Apolipoprotein(a) Kinetics in Statin-Treated Patients With Elevated Plasma Lipoprotein(a) Concentration. 2019 , 104, 6247-6255		10
165	Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives. 2019 , 33, 739-748		14
164	A new dawn for managing dyslipidemias: The era of rna-based therapies. 2019 , 150, 104413		39
163	High-density lipoprotein (HDL) particle size and concentration changes in septic shock patients. 2019 , 9, 68		32
162	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. <i>Atherosclerosis</i> , 2019 , 290, 140-205	3.1	259
161	Development of calcific aortic valve disease: Do we know enough for new clinical trials?. 2019 , 132, 189-209		41
160	LDL-C Targets in Secondary Prevention: How Low Should We Go?. <i>Current Cardiovascular Risk Reports</i> , 2019 , 13, 1	0.9	4
159	Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. <i>Atherosclerosis</i> , 2019 , 288, 194-202	3.1	35
158	Antisense Oligonucleotides Targeting Lipoprotein(a). 2019 , 21, 30		24
157	Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease. 2019 , 26, 583-591		21
156	Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2019 , 13, 374-392	4.9	156
155	Lipoprotein(a): An underrecognized genetic risk factor for malignant coronary artery disease in young Indians. 2019 , 71, 184-198		18
154	Fractional turnover of apolipoprotein(a) and apolipoprotein B-100 within plasma lipoprotein(a) particles in statin-treated patients with elevated and normal Lp(a) concentration. 2019 , 96, 8-11		8
153	What's new on therapies for elevated lipoprotein(a). 2019 , 12, 495-499		
152	Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?. 2019 , 21, 14		11

151	Role of Lipoprotein Apheresis in Cardiovascular Disease Risk Reduction. 2019 , 47, 301-316		2
150	A survival case of a young adult patient with ST-elevated myocardial infarction with high levels of lipoprotein(a). 2019 , 19, 207-210		1
149	Lipoprotein(a)-antisense therapy. 2019 , 14, 51-56		11
148	The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. 2019 , 40, 537-557		109
147	Recurrent coronary syndromes in a patient with isolated very-high lipoprotein (a) and the prothrombin genetic variant rs1799963 (G20210A): a case report. 2019 , 3, ytz019		2
146	Prognostic impact of lipoprotein(a) levels during lipid management with statins after ST-elevation acute myocardial infarction. 2019 , 30, 600-607		2
145	Molecular, Population, and Clinical Aspects of Lipoprotein(a): A Bridge Too Far?. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	9
144	Insulin Resistance Index and Proatherogenic Lipid Indices in the Offspring of People with Diabetes. 2019 , 25, 11-18		1
143	Lipoprotein(a) catabolism: a case of multiple receptors. 2019 , 51, 155-164		54
142	Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs. 2019 , 19, 113-131		2
141	Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities study. <i>Atherosclerosis</i> , 2019 , 282, 52-56	3.1	25
140	Inhibiting PCSK9 - biology beyond LDL control. 2018 , 15, 52-62		49
139	Statin therapy increases lipoprotein(a) levels. <i>European Heart Journal</i> , 2020 , 41, 2275-2284	9.5	134
138	Intensive Statin Treatment in Acute Ischaemic Stroke Patients with Intracranial Atherosclerosis: a High-Resolution Magnetic Resonance Imaging study (STAMINA-MRI Study). 2020 , 91, 204-211		19
137	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020 , 41, 111-188	9.5	2236
136	Lp(a)'s Odyssey: Should We Measure Lp(a) Post-ACS and What Should We Do With the Results?. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 145-147	15.1	2
135	Potential of Lipoprotein(a)-Lowering Strategies in Treating Coronary Artery Disease. 2020 , 80, 229-239		10
134	Lipoprotein(a) Testing and Emerging Therapies. 2020 , 28, 250-255		1

133	Lipids and lipoproteins. 2020 , 487-506		1
132	Lipoprotein (a) as a residual risk factor for atherosclerotic renal artery stenosis in hypertensive patients: a hospital-based cross-sectional study. 2020 , 19, 173		1
131	New Horizons in Pharmacologic Therapy for Secondary Stroke Prevention. 2020 , 77, 1308-1317		11
130	Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank. 2021 , 41, 465-474		32
129	Study of lipoprotein(a) and its impact on atherosclerotic cardiovascular disease: Design and rationale of the Mass General Brigham Lp(a) Registry. 2020 , 43, 1209-1215		1
128	Anti-Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial. <i>Journal of the American Heart Association</i> , 2020 , 9, e016507	6	8
127	The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. 2020 , 7, 88		29
126	Ascertainment Bias in the Association Between Elevated Lipoprotein(a) and Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2682-2693	15.1	24
125	Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options. 2020 , 52, 162-177		13
124	Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. <i>Circulation</i> , 2020 , 141, 1608-1617	16.7	52
123	Lipoprotein(a) Lowering-From Lipoprotein Apheresis to Antisense Oligonucleotide Approach. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	10
122	Impact of serum lipoprotein (a) level on coronary plaque progression and cardiovascular events in statin-treated patients with acute coronary syndrome: a yokohama-acs substudy. <i>Journal of Cardiology</i> , 2020 , 76, 66-72	3	2
121	What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?. <i>Progress in Cardiovascular Diseases</i> , 2020 , 63, 219-227	8.5	15
120	PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a). 2020 , 107, 154221		23
119	Clinical Utility of Lipoprotein(a) and LPA Genetic Risk Score in Risk Prediction of Incident Atherosclerotic Cardiovascular Disease. <i>JAMA Cardiology</i> , 2020 ,	16.2	21
118	Lipoprotein(a) and Cardiovascular Disease. 2021 , 67, 154-166		23
117	New Approaches for the Prevention and Treatment of Cardiovascular Disease: Focus on Lipoproteins and Inflammation. 2021 , 72, 431-446		5
116	Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation. 2021 , 67, 143-153		23

115	Effect of different types and dosages of statins on plasma lipoprotein(a) levels: A network meta-analysis. 2021 , 163, 105275		6
114	The association between lipoprotein (a) and carotid atherosclerosis in patients with type 2 diabetes without pre-existing cardiovascular disease: A cross-sectional study. 2021 , 171, 108622		7
113	Loci identified by a genome-wide association study of carotid artery stenosis in the eMERGE network. 2021 , 45, 4-15		5
112	The correlation between lipoprotein(a) and coronary atherosclerotic lesion is stronger than LDL-C, when LDL-C is less than 104 mg/dL. 2021 , 21, 41		4
111	Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study. 2021 ,		2
110	Pediatric dyslipidemias: lipoprotein metabolism disorders in children. 2021 , 965-1022		
109	Recent Updates of Lipoprotein(a) and Cardiovascular Disease. 2021 , 57, 36-43		3
108	Lipoprotein(a): A Cardiovascular Risk Factor Affecting Ethnic Minorities. <i>Contemporary Cardiology</i> , 2021 , 23-28	0.1	
107	Expert position statements: comparison of recommendations for the care of adults and youth with elevated lipoprotein(a). 2021 , 28, 159-173		7
106	A Synergistic Effect of Lp(a) and GRACE Score on Cardiovascular Risk in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Cohort Study From China. 2021 , 8, 637366		0
105	Lipoprotein(a) and Cardiovascular Outcomes after Revascularization of Carotid and Lower Limbs Arteries. 2021 , 11,		1
104	Emerging views of statin pleiotropy and cholesterol lowering. 2021 ,		8
103	Evolution and Outcomes of Premature Coronary Artery Disease. 2021 , 23, 36		1
102	Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics. 2021 ,		9
101	The impact of race and ethnicity on lipoprotein(a) levels and cardiovascular risk. <i>Current Opinion in Lipidology</i> , 2021 , 32, 163-166	4.4	4
100	Coronary heart disease risk: Low-density lipoprotein and beyond. 2021 ,		6
99	Association of Lipid, Inflammatory, and Metabolic Biomarkers With Age at Onset for Incident Coronary Heart Disease in Women. <i>JAMA Cardiology</i> , 2021 , 6, 437-447	16.2	27
98	Lipoprotein (a) is associated with poor long-term prognosis in patients aged 80 years and older with acute coronary syndrome. <i>Journal of Clinical Lipidology</i> , 2021 , 15, 466-476	4.9	2

97	Impact of Postprocedural High-Sensitivity C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk with ST-Segment Elevation Myocardial Infarction With Percutaneous Coronary Intervention. 2021 , 150, 8-14		0
96	Quantifying contribution of Lipoprotein (a) to atherogenic lipoprotein burden ▯ novel particle-based approach.		
95	Lipoprotein (a): When to Measure and How to Treat?. 2021 , 23, 51		2
94	Lipoprotein (a) as a treatment target for cardiovascular disease prevention and related therapeutic strategies: a critical overview. <i>European Journal of Preventive Cardiology</i> , 2021 ,	3.9	1
93	Quantifying and Understanding the Higher Risk of Atherosclerotic Cardiovascular Disease Among South Asian Individuals: Results From the UK Biobank Prospective Cohort Study. <i>Circulation</i> , 2021 , 144, 410-422	16.7	11
92	Utility of Genetically Predicted Lp(a) (Lipoprotein [a]) and ApoB Levels for Cardiovascular Risk Assessment. <i>Circulation Genomic and Precision Medicine</i> , 2021 , 14, e003312	5.2	2
91	Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies. <i>Vascular Health and Risk Management</i> , 2021 , 17, 527-542	4.4	1
90	Cardiovascular Disease Risk-Based Statin Utilization and Associated Outcomes in a Primary Prevention Cohort: Insights From a Large Health Care Network. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021 , 14, e007485	5.8	1
89	Association of Lipoprotein(a) With Recurrent Ischemic Events Following Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 2059-2068	5	2
88	Lifelong low Lp(a) levels: genetics give a green light?. <i>European Heart Journal</i> , 2021 , 42, 1157-1159	9.5	5
87	Lipoprotein metabolism in familial hypercholesterolemia. <i>Journal of Lipid Research</i> , 2021 , 62, 100062	6.3	13
86	Lipoprotein(a) Cellular Uptake Ex Vivo and Hepatic Capture In Vivo Is Insensitive to PCSK9 Inhibition With Alirocumab. <i>JACC Basic To Translational Science</i> , 2020 , 5, 549-557	8.7	12
85	Lipoprotein(a): is it more, less or equal to LDL as a causal factor for cardiovascular disease and mortality?. <i>Current Opinion in Lipidology</i> , 2020 , 31, 125-131	4.4	6
84	Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9. <i>PLoS ONE</i> , 2017 , 12, e0180869	3.7	30
83	Increased cardiovascular risk associated with hyperlipoproteinemia (a) and the challenges of current and future therapeutic possibilities. <i>Anatolian Journal of Cardiology</i> , 2020 , 23, 60-69	0.8	1
82	Poststatin Lipid Therapeutics: A Review. <i>Methodist DeBakey Cardiovascular Journal</i> , 2019 , 15, 32-38	2.1	6
81	[Association of lipoprotein (a) with ischemic stroke and stenotic carotid atherosclerosis]. <i>Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova</i> , 2020 , 120, 42-48	0.4	2
80	Effects of rosuvastatin in combination with nimodipine in patients with mild cognitive impairment caused by cerebral small vessel disease. <i>Panminerva Medica</i> , 2019 , 61, 439-443	2	7

79	Lipoprotein(a) screening in young and middle-aged patients presenting with acute coronary syndrome. <i>Cardiology Journal</i> , 2019 , 26, 511-518	1.4	6
78	Therapeutic management of hyperlipoproteinemia (a). <i>Drugs in Context</i> , 2019 , 8, 212609	5.2	7
77	Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis. <i>European Journal of Preventive Cardiology</i> , 2021 ,	3.9	10
76	Lipoprotein (a) and Cardiovascular Disease: A Missing Link for Premature Atherosclerotic Heart Disease and/or Residual Risk. <i>Journal of Cardiovascular Pharmacology</i> , 2021 ,	3.1	4
75	Pathogenetic rationale for using an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and an antioxidant coenzyme Q10 in the treatment and prevention of cardiovascular disease. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2021 , 20, 2793	0.9	
74	Residual Cardiovascular Risk Factors in Dyslipidemia.		
73	RAISED LEVEL OF LIPOPROTEIDE(A) AS A PREDICTOR OF CARDIOVASCULAR COMPLICATION POST REVASCULARIZATION OF THE LOWER EXTREMITIES ARTERIES. <i>Russian Journal of Cardiology</i> , 2018 , 7-12 ¹⁻³		
72	Lipoprotein(a) - the cardiovascular risk factor: significance and therapeutic possibilities. <i>Vnitřní Lékarství</i> , 2018 , 64, 1160-1168	0.3	1
71	Medical Treatment for Aortic Valve Disease. 2019 , 507-513		
70	Lipoprotein(a): the underutilized risk factor for cardiovascular disease. <i>Global Cardiology Science & Practice</i> , 2019 , 2019, e201911	0.7	
69	Lipoprotein (a) and the Risk of Chronic Kidney Disease in Hospitalized Japanese Patients. <i>Internal Medicine</i> , 2020 , 59, 1705-1710	1.1	0
68	Impact of Baseline LDL-C and Lp(a) Elevation on Coronary Revascularization in Patients with Acute Coronary Syndrome One-Year after First Percutaneous Coronary Intervention. <i>World Journal of Cardiovascular Diseases</i> , 2020 , 10, 102-115	0	
67	Lipoprotein(a) and High Sensitivity C-Reactive Protein among Patients with HIV in Ghana: The Study on Cardiovascular Risk Profile of HIV-Infected Patients on HAART (SCRIPT). <i>Global Heart</i> , 2020 , 15, 74	2.9	0
66	Genetic Disorders of Lipoprotein Metabolism. <i>Contemporary Cardiology</i> , 2021 , 35-80	0.1	
65	Lipoprotein (a): Principles from Bench to Bedside. <i>Contemporary Cardiology</i> , 2021 , 363-381	0.1	
64	The Role of Genetics in Preventive Cardiology: Utility of Clinically Available Genetic Tests. <i>Contemporary Cardiology</i> , 2021 , 335-364	0.1	
63	Correlation between Lipoprotein A and Prognosis of Acute Coronary Syndrome. <i>Advances in Clinical Medicine</i> , 2020 , 10, 2799-2804	0	
62	Polygenic modulation of lipoprotein(a)-associated cardiovascular risk.		

61	Predictive markers of severity of postinfarction in patients of working age who have had Q-myocardial infarction. <i>Medical Alphabet</i> , 2020 , 76-80	0.3	
60	Primary Prevention of Coronary Artery Disease. 2021 , 81-123		
59	Is there a place for rosuvastatin in the Lp(a) management?. <i>Makedonsko Farmaceutvski Bilten</i> , 2020 , 66, 85-86	0.1	
58	Effects of simvastatin and atorvastatin on biochemical and hematological markers in patients with risk of cardiovascular diseases. <i>International Journal of Clinical and Experimental Medicine</i> , 2015 , 8, 13983-9		5
57	Lipoprotein(a) Elevation: A New Diagnostic Code with Relevance to Service Members and Veterans. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2019 , 36, S19-S31	0.7	
56	Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Soci�t� Francophone d'Atheroscl�se (NSFA). <i>Archives of Cardiovascular Diseases</i> , 2021 , 114, 828-847	2.7	1
55	Screening of asymptomatic patients with elevated lipoprotein(a) levels by coronary computed tomography angiography.. <i>European Journal of Preventive Cardiology</i> , 2022 ,	3.9	
54	Lipoprotein(a). <i>Handbook of Experimental Pharmacology</i> , 2021 , 201	3.2	4
53	Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know.. <i>Progress in Cardiovascular Diseases</i> , 2022 ,	8.5	4
52	Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a)-Free Low-Density Lipoprotein Cholesterol.. <i>Journal of the American Heart Association</i> , 2022 , e023136	6	1
51	A case of hyperlipoprotein(a)emia undergoing catheter interventions for coronary artery disease, aortic valve stenosis, and peripheral artery disease.. <i>SAGE Open Medical Case Reports</i> , 2022 , 10, 20503138221074464	0.7	
50	Quantifying the contribution of Lipoprotein (a) to all apoB containing particles.. <i>Journal of Clinical Lipidology</i> , 2022 ,	4.9	
49	Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 819-836	15.1	3
48	Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target.. <i>Heart</i> , 2022 ,	5.1	0
47	Impact of lipoprotein (a) on long-term outcome after percutaneous coronary intervention in the era of new generation drug-eluting stents.. <i>Journal of Cardiology</i> , 2022 ,	3	
46	Lipoprotein(a) as risk factor for ischemic stroke. <i>Neurologie Pro Praxi</i> , 2021 , 22, 404-407	0.2	
45	Elevated Lipoprotein(a) as a potential residual risk factor associated with lipid-rich coronary atheroma in patients with type 2 diabetes and coronary artery disease on statin treatment: Insights from the REASSURE-NIRS registry.. <i>Atherosclerosis</i> , 2022 ,	3.1	1
44	Elevated Lipoprotein(a) and Risk of Atrial Fibrillation: An Observational and Mendelian Randomization Study.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 1579-1590	15.1	4

43	Lipoprotein(a) is associated with coronary atheroma progression: analysis from a serial coronary computed tomography angiography study.. <i>Journal of Geriatric Cardiology</i> , 2021 , 18, 996-1007	1.7	1
42	Role of Lipoprotein(a) in Cardiovascular Disease: A Review of Clinical Practice. 1,		
41	Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review.. <i>JAMA Cardiology</i> , 2022 ,	16.2	8
40	Recent advances in demystifying the metabolism of lipoprotein(a). <i>Atherosclerosis</i> , 2022 , 349, 82-91	3.1	8
39	Effect on the cardiovascular independent risk factor lipoprotein(a) in overweight or obese PCOS patients with ethinyl-estradiol/drospirenone alone or plus orlistat. <i>Gynecological Endocrinology</i> , 1-5	2.4	1
38	Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill?. <i>Atherosclerosis</i> , 2022 , 349, 123-135	3.1	9
37	A method for lipoprotein (a) Isolation from a small volume of plasma with applications for clinical research. <i>Scientific Reports</i> , 2022 , 12,	4.9	
36	Oxidized phospholipids on apolipoprotein B-100 versus plasminogen and risk of coronary heart disease in the PROCARDIS study. <i>Atherosclerosis</i> , 2022 ,	3.1	2
35	Lipoprotein(a): Insights for the Practicing Clinician. <i>Journal of Clinical Medicine</i> , 2022 , 11, 3673	5.1	1
34	Lipoprotein(a) When to Screen and How to Treat. <i>Current Cardiovascular Risk Reports</i> ,	0.9	
33	Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. 2022 ,		2
32	Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.		17
31	Pharmacotherapy for children with elevated levels of lipoprotein(a): future directions. 1-15		1
30	Lipoprotein a Combined with Fibrinogen as an Independent Predictor of Long-Term Prognosis in Patients with Acute Coronary Syndrome: A Multi-Center Retrospective Study. 2022 , 9, 322		0
29	Lipoprotein(a), high-sensitivity C-reactive protein, and cardiovascular risk in patients undergoing percutaneous coronary intervention. 2022 ,		1
28	Lipoprotein(a) and residual vascular risk in statin-treated patients with first acute ischemic stroke: A prospective cohort study. 13,		0
27	Temporal Trends in Lipoprotein(a) Concentrations: The Atherosclerosis Risk in Communities Study. 2022 , 11,		0
26	Familial Hypercholesterolemia and Lipoprotein(a): A Gordian Knot in Cardiovascular Prevention. 2022 , 12, 1065		1

25	Effect of an increase in Lp(a) following statin therapy on cardiovascular prognosis in secondary prevention population of coronary artery disease. 2022 , 22,	0
24	Lipoprotein(a) and Cardiovascular Disease in Chinese Population. 2022 , 2, 653-665	0
23	Recent lipoprotein(a) trials. 2022 , 33, 301-308	0
22	Lipoprotein(a) and cardiovascular disease: Make use of the knowledge we have. 2022 , 363, 75-77	0
21	Lipoprotein (a) Levels and Abdominal Aortic Aneurysm. A Systematic Review and Meta-analysis. 2022 , 28, 3492-3499	2
20	Detection strategies for elevated lipoprotein(a): will implementation let the genie out of the bottle?. Publish Ahead of Print,	0
19	Lipoprotein(a) and Atherosclerotic Cardiovascular Disease, the Impact of Available Lipid-Lowering Medications on Lp(a): An Update on New Therapies. 2022 ,	0
18	Lp(a) - an overlooked risk factor. 2023 ,	0
17	Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation Recommendations. 2023 ,	0
16	Lipid-Lowering Efficacy of Combined Lipid-Lowering Therapy and Its Effect on Glucose Metabolism. 2023 , 13, 1567-1573	0
15	Impact of Lipoprotein(a) on Macrovascular Complications of Diabetes in a Multiethnic Population in the French Amazon. 2023 , 2023, 1-7	0
14	Contemporary Aspects of Lp(a) Metabolism and Therapies Based on Tracer Kinetic Studies in Humans. 2023 , 91-111	0
13	Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial. 2023 , 17, 297-302	0
12	Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment. 2023 , 28, 969	1
11	New Therapeutic Approaches to the Treatment of Dyslipidemia 2: LDL-C and Lp(a). 2023 , 12, 37	3
10	VLDL receptor gene therapy for reducing atherogenic lipoproteins. 2023 , 69, 101685	0
9	Lipoprotein(a): Its Association with Calcific Aortic Valve Stenosis, the Emerging RNA-Related Treatments and the Hope for a New Era in Treating Aortic Valve Calcification. 2023 , 10, 96	0
8	Measurement of Lipoprotein(a) in the Clinical Laboratory. 2023 , 281-295	0

- 7 The Kidney Is the Heart of the Organs: Its Role in Lp(a) Physiology and Pathophysiology. **2023**, 207-230 ○
- 6 When Should We Measure Lipoprotein(a)? **2023**, 275-280 ○
- 5 Therapy of Elevated Lipoprotein(a). **2023**, 347-357 ○
- 4 Thrombosis, Inflammation, and Lipoprotein(a): Clinical Implications. **2023**, 189-206 ○
- 3 Association between lipoprotein(a) and peripheral arterial disease in coronary artery bypass grafting patients. ○
- 2 Lipoprotein(a): cardiovascular risk and emerging therapies. **2023**, 21, 259-268 ○
- 1 Effects of Lipid-Modifying and Other Drugs on Lipoprotein(a) Levels: Potent Clinical Implications. **2023**, 16, 750 ○